The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | Is adjuvant chemotherapy in EGFR mutated NSCLC still required?
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, provides an overview of chemotherapy in EGFR-mutated non-small cell lung cancer, highlighting new standard of care with osimertinib, as well as whether platinum-based adjuvant chemotherapy is still required. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
